May 19, 2009 by Brian Orelli, PhDFlip-Flopping: Not Just for Politicians AnymoreThe FDA's change is good for companies.
May 19, 2009 by Brian Orelli, PhDThe Cherry on Pfizer's Acquisition SundaePfizer may inherit a lawsuit.
May 18, 2009 by Brian Orelli, PhDIs There Life After 600% Returns?Don't ignore companies just because they've been on a tear.
May 12, 2009 by Brian Orelli, PhDAnother Reason to Hate Big Pharma's M&AAs if we needed another reason to shake our heads in disbelief.
May 11, 2009 by Brian Orelli, PhDBrilliant, Now Let's See the DataAstraZeneca's drug beats a blockbuster, but the devil may be in the details.
May 8, 2009 by Brian Orelli, PhDGrowth in All the Wrong Places Onyx sees growth, but a lot of it is in the wrong places.
May 8, 2009 by Brian Orelli, PhDInvesting Against Breast CancerMany companies are interested in both a cure and a large lucrative market.
May 8, 2009 by Brian Orelli, PhDGlaxo Goes Head-to-Head on HPVThe drug company takes a chance on a risky trial.
May 7, 2009 by Brian Orelli, PhDDerailed and Built to Stay That WayInvestors aren't happy with Biovail's plan to get back on track.
May 5, 2009 by Brian Orelli, PhDThe Wrong Way to Invest in the Right StocksExchange-traded funds don't work for this industry.
Apr 30, 2009 by Brian Orelli, PhDHow to Lose 75% of Your Company's Value OvernightA story of what not to do.
Apr 30, 2009 by Brian Orelli, PhDA Great Generic RecoveryAfter getting punished for taking on an acquisition, Mylan is doing pretty well.
